Alector logo

Senior Staff Scientist, Oligonucleotide Engineering

Alector

South San Francisco, CAHybridPosted 3 days ago$185,000 - $205,000/year
Full TimeSenior LevelResearch & ScientistBiotechnology
Original posting ↗

Summary

We are seeking a hands-on oligonucleotide engineering expert, with deep siRNA expertise, to serve as the scientific owner of oligonucleotide design at Alector. This is an individual-contributor role at a critical inflection point for the company, as we expand our antibody–oligonucleotide conjugate (AOC) portfolio for CNS targets.

Job description

Key Goals & Accountabilities

  • Own our oligonucleotide engineering workflow. Design and optimize siRNA sequences and chemical modification patterns for CNS targets, driving structure–activity relationships across potency, durability, metabolic stability, and off-target liabilities, and codifying the resulting design rules for the organization.
  • Apply the same engineering approach to other oligonucleotide formats as our programs call for them.
  • Extend our in silico design capability. Partner closely with our computational biology team to evolve our design pipeline — extending it to oligonucleotide formats beyond siRNA, such as ASOs, PMOs, and saRNA, and to more complex designs that improve potency and cell- and tissue-level specificity.
  • Drive externally executed oligonucleotide production. Serve as the technical owner for oligonucleotide synthesis, purification, conjugation, and characterization at external partners such as WuXi Biologics and WuXi AppTec — defining specifications and acceptance criteria, reviewing analytical data, resolving technical issues, and holding partners to program timelines and quality expectations.
  • Accelerate programs from research toward development. Partner across discovery, protein sciences, platform, and CMC teams to advance lead candidates, ensuring that sequence, chemistry, linker, and conjugation choices account for developability, process viability, and manufacturing considerations.
  • Innovate how we work. Integrate new technologies, including AI and large language models, into oligonucleotide design and data analysis workflows to accelerate programs, generate insights, and use resources more effectively.

Required Qualifications

  • PhD in nucleic acid chemistry, organic or medicinal chemistry, chemical biology, biochemistry, or a related scientific discipline with 8+ years of relevant biotechnology or pharmaceutical industry experience, or an equivalent combination of MS/MSc with 10+ years of relevant industry experience.
  • Demonstrated, hands-on expertise in siRNA engineering, including sequence design, chemical modification pattern design, and structure–activity relationship studies that informed lead selection or optimization decisions in a therapeutic program.
  • Deep working knowledge of oligonucleotide chemistry — backbone and 2′-sugar modifications, conjugation handles, and the trade-offs among potency, durability, stability, and off-target risk.
  • Demonstrated use of in silico and computational approaches to oligonucleotide design, including target site selection, off-target assessment, and comfort with scripting or data analysis tools (e.g., Python or R) to interrogate large sequence and expression datasets.
  • Track record of directing oligonucleotide synthesis, purification, and analytical work at external CRO or CDMO partners, including defining specifications and acceptance criteria and interpreting analytical data (e.g., IP-RP-UPLC, AEX, LC–MS).
  • Active user of large language models (LLMs), with a strong interest in applying evolving AI technologies to scientific research and drug development.

Preferred Qualifications

  • Hands-on experience with antibody–oligonucleotide conjugates or closely related conjugated modalities, including linker design and bioconjugation chemistry.
  • Experience with extrahepatic or CNS-directed oligonucleotide delivery, including receptor-mediated delivery approaches such as transferrin receptor targeting.
  • Hands-on experience with oligonucleotide formats beyond siRNA — for example ASOs, PMOs, saRNA, or RNA-editing oligonucleotides — and an interest in extending our platform to them.
  • Experience managing external CRO or CDMO partnerships; experience working with WuXi Biologics, WuXi AppTec, or similarly fast-paced global partners is a plus.
  • Experience mentoring scientists or leading technical workstreams without direct reporting authority, and a record of publications or patent inventorship in nucleic acid therapeutics.

Requirements

  • PhD in nucleic acid chemistry, organic or medicinal chemistry, chemical biology, biochemistry, or a related scientific discipline with 8+ years of relevant biotechnology or pharmaceutical industry experience, or an equivalent combination of MS/MSc with 10+ years of relevant industry experience
  • Demonstrated, hands-on expertise in siRNA engineering, including sequence design, chemical modification pattern design, and structure–activity relationship studies
  • Deep working knowledge of oligonucleotide chemistry — backbone and 2′-sugar modifications, conjugation handles, and trade-offs among potency, durability, stability, and off-target risk
  • Demonstrated use of in silico and computational approaches to oligonucleotide design, including target site selection and off-target assessment
  • Comfort with scripting or data analysis tools (e.g., Python or R) to interrogate large sequence and expression datasets
  • Track record of directing oligonucleotide synthesis, purification, and analytical work at external CRO or CDMO partners
  • Experience defining specifications and acceptance criteria and interpreting analytical data (e.g., IP-RP-UPLC, AEX, LC–MS)
  • Active user of large language models (LLMs) with interest in applying AI technologies to scientific research and drug development

Benefits

  • Flexible hybrid work options
  • Competitive compensation
  • Health and well-being benefits

Company overview

Alector is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative diseases and cancer. Founded in 2013 and headquartered in South San Francisco, California, the company leverages advanced antibody technology and insights from neuroimmunology to create potential first- and best-in-class medicines. Alector's pipeline includes therapeutic candidates targeting Alzheimer's disease, frontotemporal dementia, and other neurodegenerative conditions through its proprietary Alector Brain Carrier (ABC) technology designed to transport therapies across the blood-brain barrier. The company combines expertise in human genetics, neuroscience, and immunology to develop treatments that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. With approximately 240 employees, Alector operates as a publicly traded company (NASDAQ: ALEC) and has established collaborations with major pharmaceutical partners while maintaining a strong focus on creating transformative therapies for devastating brain disorders.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.